Zejula-Keytruda Combo Shows Promise in Certain Ovarian Cancer Patients in Clinical Trial

Zejula-Keytruda Combo Shows Promise in Certain Ovarian Cancer Patients in Clinical Trial
A combination of Zejula (niraparib) and Keytruda (pembrolizumab) reduced tumor size in one out of four difficult-to-treat ovarian cancer patients, Tesaro‘s Phase 1/2 trial revealed. The 25% response rate seen in the trial — called TOPACIO (NCT02657889) — was superior to that seen in historical controls treated with either drug alone. The study, “Phase 2 TOPACIO

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *